Search Bar & Filters
Found 4 Actively Recruiting clinical trials
Actively Recruiting
Researchers are studying basal cell carcinoma, a type of skin cancer, to evaluate the use of two photon fluorescence microscopy TPFM in detecting residual cancer during standard local excision surgery. The goal is to compare TPFM imaging results with the current standard method of examining surgical margins using permanent tissue sections to confirm if cancer has been fully removed. The study involves imaging excised tissue samples with TPFM to measure the distance from the tumor to the nearest inked surgical margin. After TPFM imaging, the tissue will undergo the usual histological processing with paraffin embedding and slide scanning for margin assessment. Researchers will compare the measurements from the TPFM images to the standard permanent section results to determine how well the new imaging method agrees with conventional pathology. Participants will have their excised tissue imaged with TPFM before it is processed with the standard histology methods. Researchers will collect and analyze data on the agreement between TPFM and permanent sections regarding margin distance and margin status. The primary outcome measure is the quantitative agreement between margin distances measured by TPFM and conventional histology, typically assessed 2 to 4 weeks after surgery. This study does not involve any masking or randomization and will monitor the accuracy of TPFM imaging in this clinical context.
Actively Recruiting
Researchers are evaluating a machine learning model to analyze two-photon fluorescence microscopy images of skin biopsy specimens taken during dermatology clinic visits. The study aims to see how well this imaging and analysis method agrees with traditional histology, which is the standard way to diagnose skin conditions like basal cell carcinoma and squamous cell carcinoma. Because two-photon images can be obtained from small biopsy samples within minutes, this approach could potentially allow faster diagnosis at the point of care. During the study, biopsy specimens such as punch, excisional, or shave biopsies will be imaged shortly after collection using two-photon fluorescence microscopy. A machine learning model will then assess these images and provide confidence scores for possible diagnoses including basal cell carcinoma, squamous cell carcinoma, or non-cancer. If the model has high confidence, it will provide a diagnosis otherwise, the specimen will be flagged for manual review by a pathologist. After imaging, specimens will undergo conventional histological processing to guide patient treatment. Participants will have their biopsy specimens imaged and analyzed on the same day of biopsy, while their final diagnosis will be based on histology slides reviewed by a pathologist. The study will compare the machine learning-based diagnosis with the gold-standard histology diagnosis. Researchers will measure the sensitivity and specificity of the machine learning analysis, the proportion of discordant diagnoses due to model errors, and the proportion of specimens with a definitive machine learning diagnosis. Treatment decisions remain based on conventional histology, not on the imaging method studied.
Actively Recruiting
Researchers are evaluating the use of cemiplimab, a drug that helps the immune system target cancer cells by binding to a protein called PD-1, to treat early-stage Cutaneous Squamous Cell Carcinoma CSCC, a type of skin cancer. The study compares the effects of cemiplimab injected directly into the cancer lesion with the standard treatment of surgery. The main goals include assessing side effects and determining how well cemiplimab works compared to surgery. Participants will receive either intralesional injections of cemiplimab or undergo primary surgery, which could involve Mohs surgery or other methods ensuring complete margin assessment. The study design is randomized and parallel, meaning participants are assigned to one of these two groups. Treatments and evaluations occur according to a protocol, with follow-up to monitor response and safety. During the trial, participants will be monitored through various assessments including measuring event-free survival up to three years, evaluating complete response of the target lesion at week 13, and checking for adverse events over three years. Measurements of surgical and biopsy defect sizes will also be recorded. The study involves regular visits and follow-up evaluations to track treatment effects and safety throughout participation, which lasts up to the study completion date in 2030.
Actively Recruiting
Researchers are evaluating the use of two-photon fluorescence microscopy TPFM to examine dermatologic biopsy specimens. The study aims to determine how well TPFM images, taken from biopsies in a clinic and reviewed by pathologists, agree with traditional histology results. This could help assess TPFMs accuracy in diagnosing various skin conditions such as basal cell carcinoma, squamous cell carcinoma, and melanocytic lesions. Participants biopsy specimens, including punch, excisional, or shave biopsies, will be imaged using two-photon fluorescence microscopy shortly after removal. These images will then be compared with conventional histology slides, which are reviewed by expert pathologists to establish an official diagnosis. The study also involves evaluation by a machine learning model to predict diagnoses from TPFM images. During the study, biopsy specimens will be processed and imaged with TPFM, followed by standard histological processing and scanning of slides for comparison. Researchers will measure the sensitivity and specificity of TPFM in predicting the official patient diagnoses, typically assessed 1 to 2 weeks after the biopsy procedure. The study duration extends until April 2028, with ongoing monitoring of diagnostic agreement between TPFM and conventional histology.